Skip to content
Screener

Mineralys Therapeutics, Inc. MLYS Q1 2026 earnings

Reported May 6, 2026 · After market close

EPS-$0.47Beat by $0.04
EPS estimate-$0.51

Next report

Nov 9, 2026 (in 2 months)
EPS estimate-$0.53

Financials

Q1 2026

Income statement

See full
Operating income-$45.3M-2.0%
Net income-$39.3M+6.8%
EPS (diluted)-$0.47+40.5%

Balance sheet

See full
Cash & equivalents$1.2M-14.6%
Total equity$638.1M+86.8%
Total assets$652.9M+83.9%

Cash flow

See full
Operating cash flow-$39.5M+13.2%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.23B+124%

Returns & leverage

See full
Return on equity-31%-9.6pp
Current ratio44.3×+17.8×

FAQ

When did Mineralys Therapeutics, Inc. report Q1 2026 earnings?
Mineralys Therapeutics, Inc. (MLYS) reported Q1 2026 earnings on May 6, 2026 after market close.
What were Mineralys Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Mineralys Therapeutics, Inc. reported eps of $-0.47 for Q1 2026.
Did Mineralys Therapeutics, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.51 by $0.04.
How did Mineralys Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 40.5% from $-0.79.
Where can I find Mineralys Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001933414-26-000082) and the 10-Q periodic report (0001933414-26-000084) directly on SEC EDGAR. The filing index links above go to sec.gov.